HepQuant DuO blood test to track liver recovery after alcohol-related liver disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study uses the HepQuant DuO, a blood-based test that involves a drink of the natural compound cholate and blood samples at 20 and 60 minutes, to measure liver physiology. Participants attend outpatient visits at 1, 3, 6, and 12 months during which the HepQuant DuO and standard clinical and laboratory tests are performed. The team collects clinical data, alcohol use history, symptoms, and quality-of-life measures to correlate HepQuant results with recovery. Data will be used to better monitor and treat people affected by alcohol-associated liver injury.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* adult with a clinical diagnosis of liver disease due to alcohol who have acute hepatic decompensation.

adult with a combined clinical diagnosis of alcohol-related liver disease (ALD) and nonalcoholic steatohepatitis (NASH).

Exclusion Criteria:

* Clinical diagnosis of liver disease with an etiology other than alcohol liver disease unless it is a combined clinical diagnosis of ALD and NASH.
* patients with solid organ malignancy.
* patients with other disease affecting the liver including autoimmune, drug-related liver injury, hemochromatosis or Wilson's disease
* pregnancy
* under the age of 18

Where it's running

• Stanford University Dept. of Medicine -Gastroenterology & Hepatology
  Redwood City, California, United States Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Endurance exercise to see if it lowers alcohol use in adults with AUD and ALD

  A 12-week home-based cycling program added to standard care is tested to see if it reduces alcohol use and cravings in adults with alcohol use disorder and alcohol-related liver disease.

  Recruiting The Cleveland Clinic · Cleveland, Ohio · NCT07824089

• Peer support for liver transplant recipients with a history of alcohol use disorder

  This study tests whether having a peer support specialist helps liver transplant recipients with prior alcohol use disorder stay abstinent and stay engaged in care.

  Recruiting Johns Hopkins University · Baltimore, Maryland · NCT07397598

• Prolonged steroids with NAC for severe alcoholic hepatitis

  This study tests whether adding N-acetylcysteine to prednisolone (or their placebos) improves outcomes for adults with severe alcoholic hepatitis.

  Recruiting Phase 3 University Hospital, Lille · Lille · NCT06956482

• TAK-242 and G-CSF in ACLF: a new treatment approach for adults with acute-on-chronic liver failure

  This trial tests whether adding TAK-242, with or without G-CSF, to standard ACLF care helps patients with severe alcoholic hepatitis and ACLF.

  Recruiting Phase 2 Yaqrit Ltd · London, Greater London · NCT06890039

• Identifying factors influencing alcohol relapse in liver transplant patients

  This study looks at what causes some liver transplant patients, who struggled with alcohol problems before, to relapse into drinking again after their surgery.

  Recruiting IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna · NCT06749990

• Exploring the role of gut bacteria in alcoholic hepatitis

  This study is trying to see how gut bacteria affect liver damage in people with severe alcoholic hepatitis to find new ways to help them feel better.

  Recruiting Hospices Civils de Lyon · Lyon · NCT06307964

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.